JPMorgan lowered the firm’s price target on Olema Oncology (OLMA) to $28 from $30 and keeps an Overweight rating on the shares. The firm updated models in the Smid-cap biotech group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OLMA:
- Positive Outlook on Olema Pharmaceuticals Driven by Promising Phase II Trial Results and Upcoming Phase III Initiation
- Olema Oncology Reports 2024 Financial and Clinical Progress
- Promising Clinical Data and Market Opportunities Drive Buy Rating for Olema Pharmaceuticals
- Olema Oncology price target lowered to $25 from $30 at Oppenheimer
- Olema Oncology reports Q4 EPS (51c), consensus (63c)